Free Trial

I-Mab (IMAB) Stock Price, News & Analysis

$1.60
+0.10 (+6.67%)
(As of 07/5/2024 08:52 PM ET)
Today's Range
$1.50
$1.61
50-Day Range
$1.50
$1.90
52-Week Range
$1.16
$3.17
Volume
153,100 shs
Average Volume
363,649 shs
Market Capitalization
$129.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

I-Mab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
665.6% Upside
$12.25 Price Target
Short Interest
Healthy
1.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.13) to ($1.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

310th out of 879 stocks

Pharmaceutical Preparations Industry

141st out of 417 stocks

IMAB stock logo

About I-Mab Stock (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Stock Price History

IMAB Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.
I-MAB Filed 2023 Annual Report on Form 20-F
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.
I-MAB Stock (NASDAQ:IMAB), Short Interest Report
I-Mab to Divest Chinese Unit for Up to $80M
See More Headlines
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
7/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$25.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+665.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.89 million
Book Value
$2.93 per share

Miscellaneous

Free Float
63,008,000
Market Cap
$129.41 million
Optionable
Optionable
Beta
1.08
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 60)
    CEO & Director
  • Dr. Jerry Wang
    Co-Founder & Chief Scientific Officer
  • Mr. Skelton Joseph
    Chief Financial Officer
  • Mr. Tianyi Zhang
    Vice President of Investor Relations
  • Dr. Fernando J. Salle´s Ph.D.
    Senior VP and Head of U.S. & EU Business Development
  • Claire Xu
    Head of US site
  • Ms. Min Yin (Age 54)
    Senior Vice President of Operations
  • Dr. Louie Naumovski M.D.
    Ph.D., Interim Chief Medical Officer
  • Mr. Tyler Ehler
    Senior Director of Investor Relations

IMAB Stock Analysis - Frequently Asked Questions

How have IMAB shares performed this year?

I-Mab's stock was trading at $1.90 on January 1st, 2024. Since then, IMAB stock has decreased by 15.8% and is now trading at $1.60.
View the best growth stocks for 2024 here
.

When did I-Mab IPO?

I-Mab (IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO) and Enterprise Products Partners (EPD).

This page (NASDAQ:IMAB) was last updated on 7/8/2024 by MarketBeat.com Staff

From Our Partners